Michelle E A Borm

883 citations

25 papers · 459 indexed · h-index 11

Co-authors: Chris J. Mulder Georg Kraal Adriaan A. van Bodegraven Ulf Hinz Thilo Welsch Moritz N. Wente Markus W. Büchler Luca Degrate
Topics: Rheumatoid Arthritis Research and Therapies (16 papers)Chronic Lymphocytic Leukemia Research (8 papers)Inflammatory Bowel Disease (4 papers)
Cited by: Rheumatology Gastroenterology Immunology
Journals: Gastroenterology PLoS ONE Annals of the Rheumatic Diseases
Partner nations: Netherlands Switzerland Germany

In The Last Decade

Michelle E A Borm

25 papers receiving 447 citations

Peers

Countries citing papers authored by Michelle E A Borm

Since Specialization

Citations

This map shows the geographic impact of Michelle E A Borm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle E A Borm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle E A Borm more than expected).

Fields of papers citing papers by Michelle E A Borm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle E A Borm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle E A Borm. The network helps show where Michelle E A Borm may publish in the future.

Co-authorship network of co-authors of Michelle E A Borm

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle E A Borm. A scholar is included among the top collaborators of Michelle E A Borm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle E A Borm. Michelle E A Borm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database 2021 ·BMJ Open ·(unknown),Xin Chen,Ursula Becker,Kelly A. Zalocusky,(unknown),Larry Tsai,Michelle E A Borm,Margaret Neighbors,Vincent Yau	23
2	Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab 2020 ·PLoS ONE ·Xavier M Teitsma,Jenny Devenport,Johannes W. G. Jacobs,Attila Pethö‐Schramm,Michelle E A Borm,Petra Budde,J. W. J. Bijlsma,Floris P. J. G. Lafeber	3
3	Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis 2020 ·The Journal of Rheumatology ·(unknown),Janneke Tekstra,Jacob M. van Laar,Attila Pethö‐Schramm,Michelle E A Borm,J. W. J. Bijlsma,Johannes W. G. Jacobs,Floris P. J. G. Lafeber,Paco M J Welsing	4
4	Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials 2020 ·Arthritis Care & Research ·(unknown),Janneke Tekstra,Johannes W. G. Jacobs,J. W. J. Bijlsma,Jacob M. van Laar,Attila Pethö‐Schramm,Michelle E A Borm,Floris P. J. G. Lafeber,Paco M J Welsing	3
5	Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials 2019 ·Annals of the Rheumatic Diseases ·(unknown),(unknown),Janneke Tekstra,J. W. J. Bijlsma,Jacob M. van Laar,(unknown),Michelle E A Borm,(unknown),Suzanne P. Linn-Rasker,Xavier M Teitsma,Floris P. J. G. Lafeber,Johannes W. G. Jacobs,Paco M J Welsing	14
6	AB0234 AN INTEGRATED PROTEOMICS AND ANTIBODY ANALYSIS OF THE U-ACT-EARLY TRIAL TO IDENTIFY MARKERS OF TREATMENT RESPONSE AND DISEASE PROGRESSION IN EARLY RHEUMATOID ARTHRITIS 2019 ·Annals of the Rheumatic Diseases ·(unknown),Suleiman A. Khan,Marco Prunotto,Jenny Devenport,(unknown),Michelle E A Borm,J. W. J. Bijlsma,Johannes W. G. Jacobs,Floris P. J. G. Lafeber,Paco M J Welsing,Tero Aittokallio,Antoine Soubret	1
7	Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics. 2019 ·PubMed ·Xavier M Teitsma,Johannes W G Jacobs,(unknown),Attila Pethö‐Schramm,Michelle E A Borm,Jacob M. van Laar,J. W. J. Bijlsma,Floris P. J. G. Lafeber	5
8	Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology 2018 ·Arthritis Research & Therapy ·Xavier M Teitsma,Wei Yang,Johannes W. G. Jacobs,Attila Pethö‐Schramm,Michelle E A Borm,Amy C. Harms,Thomas Hankemeier,Jacob M. van Laar,J. W. J. Bijlsma,Floris P. J. G. Lafeber	29
9	Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors 2018 ·Annals of the Rheumatic Diseases ·Xavier M Teitsma,Johannes W. G. Jacobs,Paco M J Welsing,Pascal H P de Jong,Johanna M. W. Hazes,A. Weel,Attila Pethö‐Schramm,Michelle E A Borm,Jacob M. van Laar,Floris P. J. G. Lafeber,J. W. J. Bijlsma	32
10	FRI0026 U-act-early trial 3 years follow-up. the longer effectiveness of treat-to-target strategies in early ra with tocilizumab, methotrexate, or their combination 2018 ·Annals of the Rheumatic Diseases ·(unknown),(unknown),(unknown),Attila Pethö‐Schramm,Michelle E A Borm,Xavier M Teitsma,JM van Laar,F.P. Lafeber,J. W. J. Bijlsma,Johannes W. G. Jacobs	2
11	Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy 2017 ·Lara D. Veeken ·Xavier M Teitsma,Johannes W. G. Jacobs,Paco M J Welsing,Attila Pethö‐Schramm,Michelle E A Borm,(unknown),(unknown),Jacob M. van Laar,Floris P. J. G. Lafeber,J. W. J. Bijlsma	6
12	Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy 2017 ·Arthritis Research & Therapy ·Xavier M Teitsma,Johannes W. G. Jacobs,Michal Mokrý,Michelle E A Borm,Attila Pethö‐Schramm,Jacob M. van Laar,J. W. J. Bijlsma,Floris P. J. G. Lafeber	14
13	Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies 2017 ·Lara D. Veeken ·Xavier M Teitsma,Johannes W. G. Jacobs,Paco M J Welsing,Attila Pethö‐Schramm,Michelle E A Borm,Jacob M. van Laar,Floris P. J. G. Lafeber,J. W. J. Bijlsma	14
14	OP0033 Rapid and Sustained Remission in Early Rheumatoid Arthritis (RA) Treated to Target with Tocilizumab, Methotrexate, or their Combination: The U-Act-Early Strategy Study 2015 ·Annals of the Rheumatic Diseases ·J. W. J. Bijlsma,Paco M J Welsing,Thasia Woodworth,(unknown),Corrado Bernasconi,Michelle E A Borm,F.P. Lafeber,Johannes W. G. Jacobs	4
15	Evaluation of the International Study Group of Pancreatic Surgery definition of delayed gastric emptying after pancreatoduodenectomy in a high-volume centre 2010 ·British journal of surgery ·Thilo Welsch,Michelle E A Borm,Luca Degrate,Ulf Hinz,Markus W. Büchler,Moritz N. Wente	112
16	The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype 2008 ·Genes and Immunity ·Michelle E A Borm,Adriaan A. van Bodegraven,Chris J. Mulder,Georg Kraal,(unknown)	37
17	A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis 2005 ·International Journal of Immunogenetics ·Michelle E A Borm,Adriaan A. van Bodegraven,Chris J. Mulder,Georg Kraal,(unknown)	72
18	A major quantitative trait locus on mouse chromosome 3 is involved in disease susceptibility in different colitis models 2005 ·Gastroenterology ·Michelle E A Borm,(unknown),Brian L. Kelsall,A. S. Peña,Warren Strober,Gerd Bouma	35
19	IL12B and IRF1 gene polymorphisms and susceptibility to celiac disease 2003 ·European Journal of Immunogenetics ·Diana Seegers,Michelle E A Borm,Martine J. van Belzen,Chris J. Mulder,(unknown),J. Bart A. Crusius,Jos W. R. Meijer,Cisca Wijmenga,A. S. Peña,(unknown)	23
20	Linkage analysis of colitis susceptibility in Gαi2 deficient mice unravel new loci in chromosomes not previously found in other models of experimental colitis 2003 ·Gastroenterology ·Michelle E A Borm,(unknown),(unknown),(unknown),Gerd Bouma	1

About Michelle E A Borm

Michelle E A Borm is a scholar working on Rheumatology, Genetics and Immunology, having authored 25 papers that have together received 459 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (16 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Inflammatory Bowel Disease (4 papers). The work is most often cited by research in Rheumatology (127 citations), Gastroenterology (29 citations) and Immunology (109 citations). Michelle E A Borm has collaborated with scholars based in Netherlands, Switzerland and Germany. Frequent co-authors include Chris J. Mulder, Georg Kraal, Adriaan A. van Bodegraven, Ulf Hinz, Thilo Welsch, Moritz N. Wente, Markus W. Büchler, Luca Degrate, J. W. J. Bijlsma and Attila Pethö‐Schramm. Their work appears in journals such as Gastroenterology, PLoS ONE and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact